Katus HA - Search Results

1

Anticoagulation in addition to dual antiplatelet therapy has no impact on long-term follow-up after endovascular treatment of (sub)acute lower limb ischemia.

Kronlage M, Blessing E, Müller OJ, Heilmeier B, Katus HA, Erbel C. Kronlage M, et al. Among authors: katus ha. Vasa. 2019 Jul;48(4):321-329. doi: 10.1024/0301-1526/a000786. Epub 2019 Apr 8. Vasa. 2019. PMID: 30958111

2

[A transgenic animal model: new possibilities for cardiovascular research].

Franz WM, Frey N, Müller O, Kübler W, Katus HA. Franz WM, et al. Among authors: katus ha. Z Kardiol. 1995;84 Suppl 4:17-32. Z Kardiol. 1995. PMID: 8585270 Review. German.

3

Cardiomyopathies: from genetics to the prospect of treatment.

Franz WM, Müller OJ, Katus HA. Franz WM, et al. Among authors: katus ha. Lancet. 2001 Nov 10;358(9293):1627-37. doi: 10.1016/S0140-6736(01)06657-0. Lancet. 2001. PMID: 11716909 Review.

4

Transgenic rat hearts overexpressing SERCA2a show improved contractility under baseline conditions and pressure overload.

Müller OJ, Lange M, Rattunde H, Lorenzen HP, Müller M, Frey N, Bittner C, Simonides W, Katus HA, Franz WM. Müller OJ, et al. Among authors: katus ha. Cardiovasc Res. 2003 Aug 1;59(2):380-9. doi: 10.1016/s0008-6363(03)00429-2. Cardiovasc Res. 2003. PMID: 12909321

5

Interleukin-10 suppresses tissue factor expression in lipopolysaccharide-stimulated macrophages via inhibition of Egr-1 and a serum response element/MEK-ERK1/2 pathway.

Kamimura M, Viedt C, Dalpke A, Rosenfeld ME, Mackman N, Cohen DM, Blessing E, Preusch M, Weber CM, Kreuzer J, Katus HA, Bea F. Kamimura M, et al. Among authors: katus ha. Circ Res. 2005 Aug 19;97(4):305-13. doi: 10.1161/01.RES.0000177893.24574.13. Epub 2005 Jul 21. Circ Res. 2005. PMID: 16037570

6

S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction.

Pleger ST, Remppis A, Heidt B, Völkers M, Chuprun JK, Kuhn M, Zhou RH, Gao E, Szabo G, Weichenhan D, Müller OJ, Eckhart AD, Katus HA, Koch WJ, Most P. Pleger ST, et al. Among authors: katus ha. Mol Ther. 2005 Dec;12(6):1120-9. doi: 10.1016/j.ymthe.2005.08.002. Epub 2005 Sep 15. Mol Ther. 2005. PMID: 16168714 Free article.

7

Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors.

Müller OJ, Leuchs B, Pleger ST, Grimm D, Franz WM, Katus HA, Kleinschmidt JA. Müller OJ, et al. Among authors: katus ha. Cardiovasc Res. 2006 Apr 1;70(1):70-8. doi: 10.1016/j.cardiores.2005.12.017. Epub 2006 Jan 31. Cardiovasc Res. 2006. PMID: 16448634

8

Identification of a 94-bp GC-rich element in the smooth muscle myosin heavy-chain promoter controlling vascular smooth muscle cell-specific gene expression.

Deindl E, Middeler G, Müller OJ, Selbert S, Schlenke P, Marienfeld U, Thirion C, Katus HA, Franz WM. Deindl E, et al. Among authors: katus ha. Cell Biochem Biophys. 2006;45(3):279-88. doi: 10.1385/CBB:45:3:279. Cell Biochem Biophys. 2006. PMID: 16845174

9

Targeting the heart with gene therapy-optimized gene delivery methods.

Müller OJ, Katus HA, Bekeredjian R. Müller OJ, et al. Among authors: katus ha. Cardiovasc Res. 2007 Feb 1;73(3):453-62. doi: 10.1016/j.cardiores.2006.09.021. Epub 2006 Oct 3. Cardiovasc Res. 2007. PMID: 17097076 Review.

10

Long-term administration of 3-deazaadenosine does not alter progression of advanced atherosclerotic lesions in apolipoprotein E-deficient mice.

Preusch MR, Bea F, Yang SH, Kreuzer J, Isermann B, Pedal I, Rosenfeld ME, Katus HA, Blessing E. Preusch MR, et al. Among authors: katus ha. J Cardiovasc Pharmacol. 2007 Aug;50(2):206-12. doi: 10.1097/FJC.0b013e318070c66a. J Cardiovasc Pharmacol. 2007. PMID: 17703138

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,519 results

Search Page

Filters